In summary, our findings identify the tumor-suppressive effects of ACADL through inhibiting the Hippo/YAP signaling, and provide proof of principle that inhibiting YAP activation will be a viable strategy for HCC patients with low ACADL expression. The gene discussed is ACADL; the disease is hepatocellular carcinoma.